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INTRODUCTION
The atrial natriuretic peptide (ANP) is a well known
component of the natriuretic peptide family, which also
includes BNP and CNP, and plays an important role in
the regulation of electrolytes and water balance through
its diuretic and natriuretic effects, as well as of vasomo-
tor tone through its vasorelaxant effect. Thus, ANP
maintains blood pressure homeostasis. Moreover,
through the reduction of preload and afterload as a con-
sequence of its hemodynamic effects, ANP is a key reg-
ulator of cardiac performance (1).
Since its discovery in 1981 (2), the atrial natriuretic
peptide has been largely investigated in the pathophys-
iology of several cardiovascular diseases, such as hy-
pertension, heart failure, coronary and cerebrovascular
disease (3). 
Thus, circulating and cardiac levels of ANP are di-
rectly correlated with the degree of cardiac dysfunction
in heart failure (4). Elevated ANP levels are also a hall-
mark of arterial hypertension (5, 6).
However, only through the recent introduction of 
molecular genetic techniques have we had the chance
to learn important new information on the direct contri-
bution of ANP to the individual susceptibility to develop
cardiovascular diseases (Fig. 1).
ANP and the risk of cerebro-vascular disease
Evidence from an animal model of stroke, the stroke-
prone spontaneously hypertensive rat, implicated, for
the first time, the gene encoding ANP as a direct con-
tributor to stroke susceptibility. In fact, the ANP gene
was found to map at the peak of linkage of a “protec-
tive” quantitative trait locus for stroke proneness identi-
fied in the SHRsp animal model (7). A subsequent de-
tailed analysis of the rat ANP gene revealed structural
Heart International / Vol. 2 no. 2, 2006 / pp. 78-81 © Wichtig Editore, 2006
Discovering a new role for the atrial natriuretic 
peptide: A novel risk factor for cardiovascular 
diseases
SPERANZA RUBATTU, MASSIMO VOLPE
ABSTRACT: Atrial natriuretic peptide, a diuretic, natriuretic and vasorelaxant hormone, is also
involved in the regulation of cardiovascular remodeling and it has been recently shown to be sig-
nificantly associated with higher occurrence of cardiovascular diseases. In fact, high plasma
ANP levels predict higher mortality rate for cardiovascular events. Moreover, ANP gene alter-
ations are associated with higher risk of cardiovascular intermediate phenotypes, such as left
ventricular hypertrophy, and of  cardiovascular diseases, such as stroke and hypertension.
Thus, the characterization of ANP plasma levels, and of ANP genotype for known mutations can
be proposed as an informative component of the individual cardiovascular risk profile. (Heart In-
ternational 2006; 2: 78-81)
KEY WORDS: Atrial natriuretic peptide, Cardiovascular risk, Genetic
Division of Cardiology, II Faculty of Medicine, University of Rome “La Sapienza”, Sant’Andrea Hospital, Rome - Italy;
IRCCS Neuromed, Pozzilli (Is) - ItalyRubattu et al
79
and functional alterations of this gene in the disease
prone rat, but not in its related control, the stroke-resis-
tant rat (8). In fact, presence of a promoter gene muta-
tion was associated with a significantly reduced tran-
scription of ANP in the stroke-prone rat (9). Moreover, a
coding mutation, responsible for a Gly-Ser transposi-
tion within the exon 2 of the SHRsp gene, was associat-
ed with a significant reduction of endothelial cell prolif-
eration and of the formation of new vessels (10). 
Based on robust experimental evidence, investiga-
tion of the role of ANP gene into the predisposition to
develop stroke in humans was also carried out.
Thus, it was demonstrated that carrier status for two
coding mutations, an exon 1 and an exon 3 variants,
were associated with an increased risk of cerebrovas-
cular accidents in distinct human populations. A Val-
Met transposition within exon 1 was associated with a
two-fold increased risk of stroke in the Physician’s
Health Study (11), whereas a stop codon mutation lead-
ing to a 30 rather than 28 aa long alpha-ANP was asso-
ciated with a four-fold increased risk of primary stroke
and with a three-fold increased risk of secondary stroke
in the Sardinian Stroke Study (12). The contributory ef-
fect of ANP gene molecular variants to human stroke
was independent from all conventional risk factors,
such as hypertension, diabetes, obesity, hypercholes-
terolemia, and even atrial fibrillation. 
Current studies are exploring the possible functional
implications of the ANP gene molecular variants and the
putative disease mechanisms underlying the increased
predisposition to develop vascular lesions in carriers of
such peptide variants.
In this regard, in vitro studies have previously docu-
mented an antiproliferative effect of regular ANP on rat
cultured vascular cells (13). In fact, exposure of rat en-
dothelial cells to ANP stimulated the process of apopto-
sis through the induction of p53 and the inhibition of
Bcl2 proteins (14). The proapoptotic effect of ANP was
inhibited by specific blockade of the NPR-A receptor.
Consistent results were obtained in myocardiocytes
(15). 
Of interest, parallel epidemiological observations
have reinforced the etiopathogenetic contribution of
ANP to cardiovascular events. Results from the Fram-
ingham population have underscored a predictive role
of high circulating levels of natriuretic peptides towards
an increased mortality due to cardiovascular causes
(16). Moreover, high plasma levels of natriuretic pep-
tides at the time of either a stroke or a myocardial in-
farction have been correlated with a negative prognos-
tic value for the patient, since they are associated with
an increased mortality rate within the following five
years (17).
ANP and hypertension
Convincing evidence in favour of a contributory role
of ANP in the development of hypertension has been
provided only recently through genetic approaches in
experimental animal models (18-20). In fact, ablation of
ANP gene in mice was associated with the development
of salt-sensitive hypertension (18), whereas the overex-
pression of the ANP gene in transgenic mice was asso-
ciated with reduced blood pressure levels (19). On the
other hand, ablation of the ANP receptor (NPR-A) gene
caused hypertension as well, although not of the salt-
sensitive type (20). 
Testing of ANP gene, through the candidate gene ap-
proach, in human hypertensive populations has led so
far to evidence of a significant association only in cer-
tain ethnic groups, such as African Americans (21).
Some positive results were also obtained with the char-
acterization of NPR-A gene (22). However, a more direct
demonstration of a causal role of both ANP and NPR-A
genes in the predisposition to develop hypertension in
humans is still lacking. Current studies are trying to clar-
ify this issue (unpublished observations from our
group).
Fig. 1 - Schematic representation of the major pathological effects
induced by the ANP gene alterations, i.e. structural mutations, ab-
lation and overexpression.
The modulation of cardiac mass described in both knock out and
transgenic mice is independent of BP levels. ANP and cardiovascular risk
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ANP and left ventricular hypertrophy
ANP has long been known as a marker of left ventric-
ular hypertrophy, simply as a consequence of a signifi-
cant induction of ANP gene transcription during the hy-
pertrophic process of cardiac myocytes (23). However,
we have recently learned that ANP plays an indepen-
dent, direct role on cardiac mass regulation in both ani-
mal models and in humans (18-20, 24). In fact, ablation
of ANP gene was associated with a greater ratio of heart
weight/body weight, independently from hypertension
(18), whereas the  overexpression of ANP was associat-
ed with presence of smaller hearts (19). Moreover, mice
lacking the NPR-A gene had a marked cardiac hypertro-
phy (20).  
In this regard, studies from our group have recently
demonstrated for the first time a direct modulatory role
of both ANP and NPR-A genes on cardiac mass devel-
opment in humans. In fact, an ANP promoter gene vari-
ant, associated with significantly lower levels of circu-
lating ANP, was found to associate with increased LVMI,
left ventricular posterior wall thickness, left ventricular
septum thickness, and relative wall thickening in human
essential hypertension. On the other hand, an allelic
variant of NPR-A gene was associated with increased
LVMI and left ventricular septum thickness in the same
human sample (24).
Taken together, these findings support the ANP-
NPRA system as a relevant regulatory mechanism an-
tagonizing hypertrophic growth responses within the
heart. Thus, the increase of ANP that generally accom-
panies cardiac hypertrophy should not be interpreted as
a marker of a contributory role of ANP to cardiac
growth, but rather as the response of an intrinsic
“friendly” mechanism that protects myocardiocytes
against hypertrophic stimuli (25).  
Perspectives
The traditional view of atrial natriuretic peptide as a
key regulator of blood pressure and electrolyte homeo-
stasis, as well as a marker of ventricular hypertrophy
and cardiac failure has been overcome by the new con-
cept of ANP as a cardiovascular risk factor. 
In fact, both experimental and clinical evidence show
a role for ANP in the development of all major cardio-
vascular diseases (Fig. 1).
Therefore, measurement of ANP plasma levels, and,
furthermore, assessment of the ANP genotype for the
known mutations can be proposed as important ele-
ments when assessing the cardiovascular risk profile of
an individual subject.
The future research in this exciting field will certainly
provide us with more information which, hopefully, we
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